AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
Pre-Market: $197.33 -0.11 (-0.06%) 8:12 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
Pre-Market: $197.33 -0.11 (-0.06%) 8:12 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
Gilead (GILD) Announces Positive Long-Term Results on Descovy
by Zacks Equity Research
Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.
AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure
by Zacks Equity Research
AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment
Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study
by Zacks Equity Research
Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.
The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan
Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?
by Zacks Equity Research
Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.
Top Research Reports for Apple, Facebook & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Apple (AAPL), Facebook (FB) and AbbVie (ABBV).
AbbVie (ABBV) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval
by Zacks Equity Research
Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.
Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
by Zacks Equity Research
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
The Truth About Market Timing - March 06, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Simple Secrets Anyone Can Use to Reach Early Retirement - March 06, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
AbbVie (ABBV) Stock Moves -1.21%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $90.64, moving -1.21% from the previous trading session.
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus
by Zacks Equity Research
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA
by Zacks Equity Research
Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.
Why You Shouldn't Bet Against AbbVie (ABBV) Stock
by Zacks Equity Research
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $85.62, moving +0.23% from the previous trading session.
How Trading Your Own Retirement Can Fleece Your Financial Future - February 28, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Easy Investing Secrets to an Early Retirement - February 27, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
One of Your Stock Investments is Being Acquired: Now What?
by Tracey Ryniec
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
Signs That Your Trading Will Ruin Your Retirement - February 20, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.